8-K: Propanc Biopharma Secures $41,000 in Funding Through Convertible Promissory Note

Propanc Biopharma has entered into a securities purchase agreement, securing $41,000 in funding through the issuance of a convertible promissory note with a principal amount of $49,200.

Summary

• Propanc Biopharma has obtained $41,000 in funding by issuing a convertible promissory note with a face value of $49,200 to 1800 Diagonal Lending LLC.
• The note includes a one-time interest charge of 15%, resulting in a total payback of $56,580.
• The note matures on March 30, 2025, with five scheduled payments starting November 30, 2024.
• The investor has the option to convert the outstanding principal into common stock at a 35% discount to the market price after an event of default.
• The company has the right to prepay the note at any time without penalty, and a prepayment discount is available within the first 180 days.
• The note includes various events of default, such as failure to pay, breach of covenants, and delisting of common stock.

Sentiment

Score: 4

Explanation: The document indicates a high-risk financing arrangement with a high interest rate and potential dilution for existing shareholders. While the company has secured funding, the terms are not favorable, suggesting a negative sentiment.

Positives

• The company has secured immediate funding of $41,000.
• The company has the option to prepay the note at any time without penalty.
• A prepayment discount of 3% is available within the first 180 days.
• The note is unsecured, meaning no assets are pledged as collateral.
• The company has a five-day grace period for each payment.

Negatives

• The note carries a high one-time interest charge of 15%.
• The total payback amount of $56,580 is significantly higher than the initial funding of $41,000.
• The note includes a 22% default interest rate on any unpaid amounts.
• The investor has the right to convert the note into common stock at a 35% discount after an event of default, which could dilute existing shareholders.
• The company is subject to various events of default, including financial and operational issues.

Risks

• Failure to make timely payments will trigger a 22% default interest rate.
• Breaching any covenants or representations could lead to an event of default.
• Delisting from the OTC markets or a major exchange would trigger an event of default.
• The conversion of the note into common stock could significantly dilute existing shareholders.
• The company's ability to meet its financial obligations is crucial to avoid default.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes. The company is obligated to make five payments over the next 10 months. The company must also maintain its listing on at least one of the OTC markets or a major exchange.

Management Comments

• The company intends to use the net proceeds therefrom for general working capital purposes.

Industry Context

This type of financing is common for small and micro-cap companies seeking capital, especially those that may not have access to traditional bank loans or equity markets. The terms of the note, including the high interest rate and conversion discount, reflect the higher risk associated with lending to such companies.

Comparison to Industry Standards

• The 15% one-time interest charge is relatively high compared to traditional loans, but is not uncommon for bridge financing or convertible notes for companies with higher risk profiles.
• The 35% discount on conversion is also typical for this type of financing, providing an incentive for the investor to participate.
• The cross-default provisions are standard in such agreements, ensuring that a default on one loan triggers a default on all loans with the same lender.
• The requirement to maintain a listing on a major exchange or OTC market is a common covenant to protect the investor's ability to liquidate their investment.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may be impacted by the company's financial stability and ability to operate.
• Creditors may be impacted by the company's ability to meet its financial obligations.
• Customers and suppliers may be impacted by the company's ability to continue operations.

Next Steps

• The company will make five scheduled payments to the investor starting November 30, 2024.
• The company will need to maintain its listing on at least one of the OTC markets or a major exchange.
• The company will need to manage its finances carefully to avoid triggering an event of default.

Key Dates

Keywords

convertible note, promissory note, funding, financing, securities purchase agreement, common stock, conversion, default, prepayment, interest rate